Literature DB >> 20525994

Even better kinase inhibitors for chronic myeloid leukemia.

Charles L Sawyers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20525994     DOI： 10.1056/NEJMe1004430

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Con: the case for expanded lung cancer research support.

Authors:  Mark W Geraci; Robert L Keith
Journal:  Am J Respir Crit Care Med       Date:  2011-12-01       Impact factor: 21.405

2.  Chronic Myeloid Leukaemia: A paradigm for malignancy or just a strange disease?

Authors:  Shaun R McCann
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

Review 3.  Targeted therapy in GIST: in silico modeling for prediction of resistance.

Authors:  Marco A Pierotti; Elena Tamborini; Tiziana Negri; Sabrina Pricl; Silvana Pilotti
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

4.  The challenge of developing robust drugs to overcome resistance.

Authors:  Amy C Anderson; Michael P Pollastri; Celia A Schiffer; Norton P Peet
Journal:  Drug Discov Today       Date:  2011-07-19       Impact factor: 7.851

Review 5.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Authors:  Kathryn J Chavez; Sireesha V Garimella; Stanley Lipkowitz
Journal:  Breast Dis       Date:  2010

6.  ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.

Authors:  Maria Anna Zipeto; Angela C Court; Anil Sadarangani; Nathaniel P Delos Santos; Larisa Balaian; Hye-Jung Chun; Gabriel Pineda; Sheldon R Morris; Cayla N Mason; Ifat Geron; Christian Barrett; Daniel J Goff; Russell Wall; Maurizio Pellecchia; Mark Minden; Kelly A Frazer; Marco A Marra; Leslie A Crews; Qingfei Jiang; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-06-09       Impact factor: 24.633

7.  Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations.

Authors:  I Glauche; K Horn; M Horn; L Thielecke; M A G Essers; A Trumpp; I Roeder
Journal:  Br J Cancer       Date:  2012-04-26       Impact factor: 7.640

Review 8.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

9.  Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.

Authors:  Hemanth Naick Banavath; Om Prakash Sharma; Muthuvel Suresh Kumar; R Baskaran
Journal:  Sci Rep       Date:  2014-11-10       Impact factor: 4.379

10.  STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.

Authors:  Wolfgang Warsch; Eva Grundschober; Angelika Berger; Lars Gille; Sabine Cerny-Reiterer; Anca-Sarmiza Tigan; Andrea Hoelbl-Kovacic; Peter Valent; Richard Moriggl; Veronika Sexl
Journal:  Oncotarget       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.